Table 1 Patients’ characteristics
Variables | No | % |
|---|---|---|
Gender | ||
Male | 49 | 49% |
Female | 51 | 51% |
Age/years | ||
≤ 60 | 52 | 52.0 |
> 60 | 48 | 48.0 |
HCV seropositivity | ||
Yes | 33 | 33% |
No | 67 | 67% |
Serum LDH | ||
Normal | 21 | 21% |
Elevated | 79 | 79% |
B symptoms | ||
No | 56 | 56% |
Yes | 44 | 44% |
Involved sites | ||
Nodal | 74 | 74% |
Extra-nodal | 26 | 26% |
BM infiltration | ||
No | 73 | 73% |
Yes | 20 | 20% |
Biopsy not done | 7 | 7% |
Ann Arbor stage | ||
I and II | 15 | 15% |
III and IV | 85 | 85% |
IPI risk | ||
Low | 13 | 13% |
Low intermediate | 34 | 34% |
High intermediate | 33 | 33% |
High | 20 | 20% |
Histological type | ||
Centroblastic | 72 | 72% |
Immunoblastic | 19 | 19% |
Anaplastic | 9 | 9% |
Hans classification | ||
GC | 22 | 22% |
Non-GC | 78 | 78% |
P53 expression (N = 85) | ||
No over expression | 66 | 77.6% |
Over expression | 19 | 22.4% |
Double expressor | ||
No | 72 | 72% |
Yes | 28 | 28% |
Triple expressor | ||
No | 92 | 92% |
Yes | 8 | 8% |
PD-L1 expression | ||
Low | 27 | 27% |
High | 73 | 73% |
Treatment response | ||
CR | 42 | 42% |
PR | 11 | 11% |
SD | 3 | 3% |
PD | 44 | 44% |
Relapse after CR (N = 42) | ||
No | 28 | 67% |
Yes | 14 | 33% |